Management of epilepsy in brain tumor patients
Cet article analyse la prise en charge de l'épilepsie chez les patients atteints d'une tumeur cérébrale
Isocitrate dehydrogenase mutation and its active metabolite d-2-hydroxyglutarate seem important contributing factors to epileptogenesis. Antiepileptic drug (AED) levetiracetam seems the preferred choice in brain tumor-related epilepsy. In case of inadequate seizure control on AED monotherapy, potential add-on AEDs include lacosamide, perampanel, and valproic acid. In the end-of-life phase when oral intake of medication is hampered, benzodiazepines via nonoral administration routes are potential alternatives.